Skip to main content
. 2015 Nov 9;35(26):3465–3475. doi: 10.1038/onc.2015.409

Figure 2.

Figure 2

Immunohistochemical localization of PML and CRM1 in prostate cancer patients' TMA. (a) Lack of cytoplasmic PML and (c) CRM1 in benign tissue. (b) Nuclear and cytoplasmic localization of PML and (d) CRM1 in cancer. (e) Kaplan–Meier plot. Scale bars as indicated.